The myPath Test for Melanoma

July 2, 2014
Loren Clarke, MD

Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses the company’s new myPath test for melanoma

Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses the company’s new myPath test for melanoma.

Clinical Pearls:

  • There are approximately 1.5 million biopsies done in the United States each year for atypical moles in an effort to exclude the possibility of melanoma.
  • Approximately 15% of these biopsies are difficult to diagnose.
  • The myPath test is objective and produces a single score that can help differentiate malignant melanoma from a benign nevus.